The largest database of trusted experimental protocols

Pcmv6 ac gfp plasmid

Manufactured by OriGene
Sourced in United States

The PCMV6-AC-GFP plasmid is a commercially available expression vector designed for the expression of proteins in mammalian cell lines. The plasmid contains the cytomegalovirus (CMV) promoter, which drives the expression of the green fluorescent protein (GFP) reporter gene. This plasmid can be used for transient or stable transfection experiments to monitor gene expression in cells.

Automatically generated - may contain errors

10 protocols using pcmv6 ac gfp plasmid

1

PPARG and ABCG1 Expression Plasmids

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human peroxisome proliferator–activated receptor-γ (PPARG) cDNA cloned into pCMV-SPORT6 plasmid was obtained from Thermo Scientific, and human ABCG1 cDNA cloned into pCMV6-AC-GFP plasmid was purchased from OriGene.
+ Open protocol
+ Expand
2

Targeted Knockdown and Overexpression of Key Regulators

Check if the same lab product or an alternative is used in the 5 most similar protocols
Notch3, c-Myc, STAT3, mTOR, and PD-L1 were knocked down using specific SiRNA (supplementary Table 1) and the transfection reagent Lipofectamine RNAiMAX reagent (Life technologies, USA) as per manufacturer’s instructions. Briefly, cells were plated 1 day before transfection in regular medium. Transfection was done in Optimum medium (Life technologies, USA) serum-free. Medium was supplemented with 8% serum 48 h after transfection. Cells were harvested 72 h after transfection.
STAT3 and c-Myc were also downregulated using specific ShRNA from OriGene (USA) in lentiviral vectors, (TL301348V, and TL311323V, respectively, using pGFP-C-ShLenti vector) as previously described9 (supplementary Table 2). Among the four plasmids (A, B, C, and D) provided by the company for each gene knockdown, plasmids (B) were the most effective in downregulating c-Myc and STAT3 in MDA-MB-231 cells (supplementary figure 11).
Notch3 was overexpressed by transfection with GFP-tagged Notch3 ORF in pCMV6-AC-GFP plasmid (cat# RG224711) obtained from Origene (Rochville, MD, USA). pCMV6-AC-GFP plasmid lacking the ORF (empty vector = EV) was used as a transfection control. Transfection was done using Lipofectamine LTX (Invitrogen, USA) and selection was done with G418 (Sigma, USA).
+ Open protocol
+ Expand
3

FMN1 Overexpression Modulates Cisplatin Sensitivity

Check if the same lab product or an alternative is used in the 5 most similar protocols
FMN1 was overexpressed in U-1810 cells by transfecting cells with the FMN1 open reading frame cDNA integrated in the pCMV6-AC-GFP plasmid (OriGene, Rockville, Maryland, USA), using Lipofectamine LTX reagent (Invitrogen, Germany). Briefly, U1810 cells were seeded in 6-well plates and transfected with 2 μg of pCMV6-AC-GFP FMN1 plasmid for 24 h. As a control, cells only treated with Lipofectamine were used. The next day, media was removed, and normal growth media (RPMI-1640) was added to each well for another 24 h. Western blot analysis was used to confirm the overexpression of FMN1 at the point of cisplatin treatment using a FMN1 antibody (Abcam, Cambridge, UK). To assess the effect on proliferation and cisplatin sensitivity, cells were seeded in 96-well plates (8000 cells/well), and the next day treated with indicated concentrations of cisplatin for 72 h. The cytotoxicity of cisplatin was determined with (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium) (MTT) assay as described above. Survival of cells is given by comparing the absorbance in treated cells relative to the absorbance in cells only treated with Lipofectamine. Three separate transfections were performed with triplicate technical repeats in the MTT. Data presented is the mean ± SEM.
+ Open protocol
+ Expand
4

Plasmid Transformation and Purification

Check if the same lab product or an alternative is used in the 5 most similar protocols
A plasmid encoding C-terminal green fluorescent protein (GFP)-tagged NDRG2 (pCMV6–AC–GFP-NDRG2) and a negative control pCMV6–AC-GFP plasmid without NDRG2 (mock plasmid) were purchased from OriGene (OriGene, USA). The competent Escherichia coli strains DH5α were used for proliferation of plasmid constructs. For each transformation, 100 ng of DNA was added to 25 μl of competent cells and incubated on ice for 30 min, followed by heat shock at 42 °C for 2 min and incubation on ice for 2 min. The cells were allowed to recover in 1 ml Luria-Bertani (LB) broth and then incubated for 60 min at 37 °C with shaking. Cells were plated on LB-agar plate containing 100 μg/ml ampicillin (plasmids encoded ampicillin resistance) and incubated at 37 °C overnight to select the transformants. After overnight culture, one colony of each plasmid was transferred to 3 ml of LB broth supplemented with ampicillin (50 μg/ml) for 5 hr of pre-culture at 37 °C before transfer to 500 ml LB broth for a further overnight of incubation in a rotating incubator. The overnight culture was centrifuged at 5000 g for 10 min, and the resulting pellet was used to extract plasmid DNA using PureLink™ HiPure plasmid filter Purification Kit (Invitrogen, UK) as per manufacturer’s instructions. The concentration of the DNA extracted was measured using the NanoDrop ND-100 spectrophotometer.
+ Open protocol
+ Expand
5

Characterization of BRAF and SND1-BRAF Variants

Check if the same lab product or an alternative is used in the 5 most similar protocols
pCMV6-AC-GFP plasmid containing cDNA of a wild type BRAF and SND1-BRAF fusion gene were synthesized and purchased from Origene (Rockville, MD, USA). The BRAFV600E construct was generated using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent, CA, USA) and verified by Sanger sequencing. The wild type BRAF construct was used as a BRAFV600E mutagenesis template. The NCI-H1299 large cell lung cancer cell line with wild type of EGFR from a male Caucasian was purchased from ATCC (USA). H1299 cells were maintained in RPMI1640 (Life Technologies, USA) supplemented with 10% FBS (Life Technologies) and 1% antibiotics (Life Technologies). Transfection was performed by using Lipofectamine 2000 (Life Technologies) as instructed by the manufacturer.
+ Open protocol
+ Expand
6

Transient Transfection of Ion Channels in CHO Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
CHO cells were transiently transfected using Lipofectamine 2000 kit (Invitrogen), as per manufacturer’s protocol with the following ion channel coding vectors: hKV1.1 (hKCNA1 gene) and hKV1.2 (hKCNA2 gene) in pCMV6-AC-GFP plasmid (cat# RG211000 and RC222200; OriGene Technologies), hKV1.5 in pEYFP plasmid (a kind gift from A. Felipe, University of Barcelona, Barcelona, Spain), hKCa3.1 (hKCNN4 gene) in pEGFP-C1 vector (a kind gift from H. Wulff, University of California, Davis, Davis, CA), hNaV1.5 (hSCN5A, a kind gift from H. Abriel, University of Bern, Bern, Switzerland), and hHv1 (hVCN1, GenBank accession no. BC007277.1, a kind gift from Kenton Swartz, National Institutes of Health, Bethesda, MD). At 24 h after transfection, GFP-expressing transfectants were identified with Nikon TE 2000U fluorescence microscope using bandpass filters of 455–495 and 515–555 nm for excitation and emission, respectively, and used for current recordings (∼60–70% success rate for co-transfection). In general, currents were recorded 24–36 h after transfection.
Human embryonic kidney 293 cells stably expressing hKV11.1 (hERG1 and hKCNH2 genes, a kind gift from H. Wulff), mKCa1.1 (BKCa, mKcnma1, a kind gift from C. Beeton, Baylor College of Medicine, Houston, TX), and hNaV1.4 (hSCN4A gene, a kind gift from P. Lukács, Eötvös Loránd University, Budapest, Hungary) were used.
+ Open protocol
+ Expand
7

GFP-Tagged PCSK9 Protein Expression

Check if the same lab product or an alternative is used in the 5 most similar protocols
A pCMV6-AC-GFP plasmid coding for the PCSK9 gene was purchased from OriGene Technologies (Rockville, MD, USA, Cat No. RG220000). After in vitro synthesis driven by a CMV promoter, the PCSK9 protein harbored a GFP (green fluorescent protein) at its C end, resulting in a GFP-tagged PCSK9 protein. This made the use of applications directed to GFP protein detection possible in a sample, e.g., by fluorescence detection and/or by induction of anti-GFP antibodies.
+ Open protocol
+ Expand
8

Modulation of EGFR and PTPN9 in Cell Culture

Check if the same lab product or an alternative is used in the 5 most similar protocols
All cell lines were maintained in DMEM supplemented with 10% fetal bovine serum, 1% penicillin and streptomycin, and 1% non-essential amino acid. For EGFR knock down experiment, cells were transfected with Dharmacon siGENOME non-target siRNA or EGFR SMARTpool siRNA following manufacturers instruction (Thermo Scientific, MA, USA). For PTPN9 overexpression, cells were transfected with PTPN9 in the pCMV6-AC-GFP plasmid (Origene, MD, USA) using the Amaza Basic Glial Cells Nucleofector Kit (Lonza, Germany) following manufacturers instructions.
+ Open protocol
+ Expand
9

Pharmacological Manipulation of Ion Currents

Check if the same lab product or an alternative is used in the 5 most similar protocols
Drugs were bath-applied during the protocol and some experiments were performed using a drug “cocktail” containing TEA (15 mM), TTX (0.5 µM) and CsCl (1 mM). We used TEA to block the M-currents [1 (link)], TTX to block sodium currents and CsCl to inhibit the hyperpolarization-activated cationic H-current [51 (link)].
All chemicals were obtained from Sigma-Aldrich (Madrid, Spain), except TTX that was purchased from Tocris Bioscience (Bristol, UK), pCMV6-AC-GFP plasmid belonging to Origene (Rockville, MD, USA) and Lipofectamine 3000 kit from Invitrogen (Life Technologies, California, CA, USA).
+ Open protocol
+ Expand
10

Quantitative NHEJ Repair Capacity Monitoring

Check if the same lab product or an alternative is used in the 5 most similar protocols
The Host-cell Reactivation system by Nagel et al. [26 (link)] was expanded to provide per-cell quantitative NHEJ pathway capacity monitoring of blunt end, 5’-3’ and 3’-5’ discontiguous dephosphorylated mismatched overhang DNA double-strand breaks. XL1-Blue supercompetent cells (200236; Agilent) were transformed with reconstituted pCMV6-AC-GFP plasmid (ps100010; Origene). EcoRI-HF (R3101S), SacI-HF (R3156S), KpnI-HF (R3142S), PmeI (R0560S), and Quick CIP (M0525) (New England Biolabs) were used to construct three dephosphorylated DSB plasmid conformations. Explants were plasmid transfected (lipofectamine LTX or 3000 (15338-100, 11668-027; Thermo Fisher)). Cultures were monitored at 24, 48 and 72 h. Fluorescence-governed NHEJ pathway activity was assessed qualitatively (microscopy) and quantitatively (flow cytometry). Event monitoring provides per-cell resolution of intra-explant NHEJ repair capacity variance and enables the detection of basal-level NHEJ activity. Ordinal plasmid condition scores were integrated to provide Explant capacity scores for explant NHEJ repair capacity. Further details are provided in Supplementary Information Sections 1.4 and 2.3.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!